Post Subject #221579   0 IPH.PA +37% on multifaceted AZN I-O collaboration—and equity stake: DewDiligence 10/23/18 01:09:32 PM #221577   0 ENTA—EDP-938 (RSV) update on phase-1/phase-2 trials: DewDiligence 10/23/18 10:46:50 AM #221558   0 Nektar Therapeutics plunges as Roche data seen as jbog 10/22/18 04:29:05 PM #221543   0 NTGN: If you hadn't already figured it RockRat 10/22/18 12:51:01 PM #221318   0 Hi, JL. RVNC's RT002 appears to attenuate diffusion DewDiligence 10/10/18 11:19:46 AM #220844   0 Allergan pursuit of longer-acting toxin not a risk jbog 09/14/18 11:13:21 AM #221584   0 AMRN. Dew , re their balance sheet . Whalatane 10/23/18 03:45:53 PM #221583   0 SELB -33% on (more) phase-2 gout data: DewDiligence 10/23/18 03:36:57 PM #221582   0 ENTA—This is the ct.g listing for the phase-2 DewDiligence 10/23/18 02:12:49 PM #221581   0 Results as early as July or late as CT 10/23/18 02:01:13 PM #221580   0 Addendum re ENTA’s RSV program: DewDiligence 10/23/18 01:54:11 PM #221579   0 IPH.PA +37% on multifaceted AZN I-O collaboration—and equity stake: DewDiligence 10/23/18 01:09:32 PM #221578   0 PTI bouncing on news deal might get done RockRat 10/23/18 01:04:24 PM #221577   0 ENTA—EDP-938 (RSV) update on phase-1/phase-2 trials: DewDiligence 10/23/18 10:46:50 AM #221576   0 "In cancer research, the total efficacy of combination swampboots 10/23/18 10:42:25 AM #221575   0 5-day chart looks like a buy if you robtewms 10/23/18 10:12:31 AM #221574   0 I don't have an education opinion on ACST. DewDiligence 10/23/18 09:42:58 AM #221573   0 I haven’t looked at AMRN’s balance sheet lately. DewDiligence 10/23/18 09:41:30 AM #221572   0 Here’s the PR for NVS’s 2011 buyout of DewDiligence 10/23/18 09:37:42 AM #221571   0 NEO "[NeoGenomics Signs Definitive Agreement to Acquire Genoptix/i] apljack 10/23/18 08:47:52 AM #221570   0 Any thoughts on acst? ronpopeil 10/22/18 08:21:04 PM #221569   0 so why hasn't Amarin dilute yet? it has linhdtu 10/22/18 08:18:25 PM #221568   0 Friday morning's BLRX PR was a harbinger! DewDiligence 10/22/18 07:10:30 PM #221567   0 IMGN—(-16%)—was not of the of exceptions to #msg-144374988: DewDiligence 10/22/18 07:07:46 PM #221566   0 DVAX—(+11%)—was one of the few exceptions: DewDiligence 10/22/18 06:55:04 PM #221565   0 SLS -14% on Neuvax TNBC data at ESMO—stock DewDiligence 10/22/18 06:32:47 PM #221564   0 KURA recovered a little to close -19%. Did DewDiligence 10/22/18 06:27:50 PM #221563   0 $MRZM $1.60 pps - recently Acquired Protease love your neighbor 10/22/18 06:05:27 PM #221561   0 NTGN—I concur with the viewpoint in your Twitter DewDiligence 10/22/18 05:04:23 PM #221560   0 What were they waiting for? You gotta strike DewDiligence 10/22/18 04:39:43 PM #221559   0 PTI a bit slow by the standards of RockRat 10/22/18 04:37:40 PM #221558   0 Nektar Therapeutics plunges as Roche data seen as jbog 10/22/18 04:29:05 PM #221557   0 NKTR—...the awareness that anyone can work on a DewDiligence 10/22/18 04:00:30 PM #221556   0 sorry, I should read this forum in a dangerM 10/22/18 03:55:35 PM #221554   0 …NKTR has a collaboration with SNDX (where they DewDiligence 10/22/18 03:52:58 PM #221553   0 ... or RO6874281 (IL2-FAP fusion protein) at ESMO dangerM 10/22/18 03:52:00 PM #221552   0 I saw someone tweet something about Roches IL-2 ghmm 10/22/18 02:44:04 PM #221551   0 True. Unlike many odd-looking clinical results, there's a DewDiligence 10/22/18 01:50:53 PM #221550   0 Keytruda monotherapy bests chemo in OS for PD-L1+ dewophile 10/22/18 01:48:10 PM #221549   0 ADRO -34% in sympathy with MRK’s weak results DewDiligence 10/22/18 01:28:13 PM #221548   0 MRK—Keytruda data in first-line H&N cancer from KEYNOTE-048 study: DewDiligence 10/22/18 01:19:13 PM #221547   0 Yes, that too (eom). DewDiligence 10/22/18 01:05:30 PM #221546   0 It seems the Bavencio + axitinib data in dewophile 10/22/18 01:02:12 PM #221545   0 By and large, ESMO—>disaster for presenting companies. vlad33301 10/22/18 01:00:09 PM #221543   0 NTGN: If you hadn't already figured it RockRat 10/22/18 12:51:01 PM #221542   0 AVEO -9% on ESMO data: DewDiligence 10/22/18 11:46:57 AM #221541   0 LPTX -10% on ESMO data: DewDiligence 10/22/18 11:43:46 AM #221540   0 NCNA -8% on ESMO data: DewDiligence 10/22/18 11:41:27 AM #221539   0 By and large, ESMO—>disaster for presenting companies. DewDiligence 10/22/18 11:39:23 AM #221538   0 CTMX -8% on ESMO data: DewDiligence 10/22/18 11:38:52 AM #221537   0 MRTX -17% on Sitravatinib mono/combo data at ESMO: DewDiligence 10/22/18 11:34:42 AM #221536   0 BMY -5% on TMB mess—and 3-month delay in DewDiligence 10/22/18 11:26:42 AM #221535   0 NKTR -16%—likely related to the discussion in the DewDiligence 10/22/18 11:23:19 AM #221534   0 SNDX -20% on no news—sell-off could be related DewDiligence 10/22/18 11:21:27 AM #221533   0 EPZM -7% on phase-2 Tazemetostat data in sarcoma, DewDiligence 10/22/18 11:14:30 AM #221532   0 NTGN -15% on phase-1 NEO-PV-1 data at ESMO: DewDiligence 10/22/18 11:03:20 AM Post Subject

© 2018 InvestorsHub.com, Inc.